Citi analyst Patrick Donnelly lowered the firm’s price target on Bio-Rad (BIO) to $350 from $400 and keeps a Buy rating on the shares following the Q1 report. While Q1 beat estimates, the company lowered the fiscal year growth guidance by 225 basis points to reflect softer demand among U.S. academic, government and biotech customers, particularly on the instrument business, the analyst tells investors in a research note. The firm updated Bio-Rad’s model for the quarter and guidance.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue